Chimeric Therapeutics is trading 54.29% down at A$0.02 after resuming from a trading halt on August 19, 2026; available evidence does not identify a confirmed cause.
- The halt was requested pending an announcement concerning results from the company’s CDH17 clinical trial, but the available evidence does not disclose the results or explicitly attribute the decline to them.
- Broader markets were broadly stable, so there is no confirmed global-market explanation. Trading volume and activity levels were unavailable.